GLP-1 Trends
GLP-1 agonists have become increasingly popular as a treatment option for type 2 diabetes and obesity. These medications continue to dominate the market for traditional drug spend as they expand into new indications and formulations. For example, Wegovy® (semaglutide), a GLP-1 medication, has recently received approval for a new indication: to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
Fill out the form below to download our trend report to learn more about glucagon-like peptide-1 (GLP-1) receptor agonists and how Maxor’s disease management improves member adherence and could improve member outcomes.
